Circulating Tumor DNA and Unique Actionable Genomic Alterations in the Longitudinal Monitoring of Metastatic Breast Cancer: A Case of FGFR2-KIAA1598 Gene Fusion

Article Tools CASE REPORTS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/PO.22.00702 JCO Precision Oncology no. 7 (2023) e2200702. Published online July 12, 2023. PMID: 37437229 Circulating Tumor DNA and Unique Actionable Genomic Alterations in the Longitudinal Monitoring of Metastatic Breast Cancer: A Case of FGFR2-KIAA1598 Gene Fusion Eleonora Nicolò , MD1,2,3xEleonora NicolòSearch for articles by this author; Laura Munoz-Arcos , MD3xLaura Munoz-ArcosSearch for articles by this author; Elena Vagia, MD4xElena VagiaSearch for articles by this author; Paolo D'Amico , MD4xPaolo D'AmicoSearch for articles by this author; Carolina Reduzzi , PhD3,4xCarolina ReduzziSearch for articles by this author; Jeannine Donahue, BS3,4xJeannine DonahueSearch for articles by this author; Marco Lorico-Rappa , MBBS4,5xMarco Lorico-RappaSearch for articles by this author; Maroua Manai, PhD3,4xMaroua ManaiSearch for articles by this author; Amir Behdad, MD4xAmir BehdadSearch for articles by this author; Youbin Zhang, MD, PhD4xYoubin ZhangSearch for articles by this author; Giuseppe Curigliano, MD, PhD1,2xGiuseppe CuriglianoSearch for articles by this author; Ami Shah , MD4xAmi ShahSearch for articles by this author; and Massimo Cristofanilli , MD, FACP3,4xMassimo CristofanilliSearch for articles by this author Show More 1Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy2Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy3Department of Medicine, Division of Hematology-Oncology, Weill Cornell Medicine, New York, NY4Department of Medicine-Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL5Royal College of Surgeons School of Medicine, Dublin, Ireland https://doi.org/10.1200/PO.22.00702 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologySUPPORTEleonora Nicolò was supported by an American-Italian Cancer Foundation Post-Doctoral Research Fellowship.AUTHOR CONTRIBUTIONSConception and design: Eleonora Nicolò, Laura Munoz-Arcos, Carolina Reduzzi, Massimo CristofanilliFinancial support: Massimo CristofanilliAdministrative support: Jeannine DonahueProvision of study materials or patients: Massimo CristofanilliCollection and assembly of data: All authorsData analysis and interpretation: Eleonora Nicolò, Laura Munoz-Arcos, Massimo CristofanilliManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Paolo D’AmicoEmployment: MerckStock and Other Ownership Interests: MerckResearch Funding: Roche Italy (Inst)Carolina ReduzziResearch Funding: Menarini Silicon BiosystemsAmir BehdadHonoraria: Roche China, Lilly, Leica Biosystems, Caris Life SciencesConsulting or Advisory Role: Caris Life Sciences, Leica BiosystemsSpeakers’ Bureau: Lilly, Roche ChinaTravel, Accommodations, Expenses: Bayer, Foundation Medicine, PfizerGiuseppe CuriglianoHonoraria: Ellipses PharmaConsulting or Advisory Role: Roche/Genentech, Pfizer, Novartis, Lilly, Foundation Medicine, Bristol Myers Squibb, Samsung, AstraZeneca, Daichi-Sankyo, Boehringer Ingelheim, GlaxoSmithKline, Seagen, Guardant Health, Veracyte, Celcuity, Hengrui Pharmaceuticals, Menarini, MerckSpeakers’ Bureau: Roche/Genentech, Novartis, Pfizer, Lilly, Foundation Medicine, Samsung, Daiichi Sankyo, Seagen, MenariniResearch Funding: Merck (Inst)Travel, Accommodations, Expenses: Roche/Genentech, Pfizer, Daiichi SankyoAmi ShahHonoraria: Gilead SciencesConsulting or Advisory Role: AstraZeneca/MedImmune, Gilead SciencesMassimo CristofanilliHonoraria: PfizerConsulting or Advisory Role: Lilly, Menarini, Olaris, AstraZeneca/Daiichi Sankyo, Syantra, Sermonix Pharmaceuticals, CelcuityResearch Funding: Lilly, Angle, Merck, AstraZeneca, Menarini Silicon BiosystemsNo other potential conflicts of interest were reported.